Ginkgo Bioworks Holdings, Inc. $DNA Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC cut its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 91.0% in the third quarter, HoldingsChannel.com reports. The fund owned 13,565 shares of the company’s stock after selling 136,406 shares during the period. FNY Investment Advisers LLC’s holdings in Ginkgo Bioworks were worth $197,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DNA. AQR Capital Management LLC lifted its holdings in Ginkgo Bioworks by 322.6% during the first quarter. AQR Capital Management LLC now owns 158,939 shares of the company’s stock valued at $906,000 after purchasing an additional 121,326 shares in the last quarter. Millennium Management LLC increased its stake in shares of Ginkgo Bioworks by 113.1% during the first quarter. Millennium Management LLC now owns 1,427,600 shares of the company’s stock worth $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of Ginkgo Bioworks by 25.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company’s stock worth $3,915,000 after purchasing an additional 139,126 shares during the last quarter. Acadian Asset Management LLC acquired a new position in shares of Ginkgo Bioworks during the 1st quarter worth about $120,000. Finally, Savant Capital LLC purchased a new position in Ginkgo Bioworks in the 2nd quarter valued at about $183,000. 78.63% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Trading Up 6.2%

NYSE:DNA opened at $6.90 on Friday. The company has a market cap of $417.77 million, a P/E ratio of -1.22 and a beta of 1.58. Ginkgo Bioworks Holdings, Inc. has a twelve month low of $5.00 and a twelve month high of $17.58. The company’s 50-day moving average price is $8.58 and its 200-day moving average price is $10.01.

Ginkgo Bioworks (NYSE:DNA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($1.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.38. Ginkgo Bioworks had a negative net margin of 183.81% and a negative return on equity of 52.82%. The company had revenue of $33.40 million during the quarter, compared to analysts’ expectations of $37.57 million. On average, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ginkgo Bioworks in a report on Wednesday, January 21st. BTIG Research decreased their target price on Ginkgo Bioworks from $9.00 to $5.00 and set a “sell” rating on the stock in a research report on Thursday, March 12th. TD Cowen lowered their price target on Ginkgo Bioworks from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research note on Sunday, March 8th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Reduce” and a consensus target price of $8.50.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a synthetic biology company that designs custom microbes for customers across a range of industries. Utilizing a proprietary organism foundry platform, the company engineers cells to produce high-value chemicals, enzymes, and other biological materials. By integrating automation, data analytics and machine learning, Ginkgo Bioworks seeks to accelerate the development of biologically derived solutions at industrial scale.

The company’s services span the entire development cycle, from genetic design and strain optimization to fermentation and downstream processing.